Objective: It has been shown that cGMP content is reduced in post-ischemic myocardium, and that stimulation of cGMP synthesis prevents cardiomyocyte hypercontracture and cell death in vitro. This study was aimed at determining whether administration of the natriuretic peptide urodilatin (URO) at the time of reperfusion could limit myocardial cell death secondary to transient coronary occlusion.
Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs a a , a a a *´´F erran Padilla , David Garcia-Dorado , Luis Agullo , Jose A. Barrabes , Javier Inserte , a b a a a
Introduction during the initial minutes of reperfusion [2]
, and results in a characteristic 'histological pattern of contraction band During myocardial reperfusion, excessive contractile necrosis ' [3] , the most prominent type of necrosis observed activation resulting from restoration of energy supply in after early reperfusion [4] [5] [6] . If hypercontracture is pre- 21 the presence of abnormally high cytosolic Ca may result vented by transiently blocking contractility during the in disruption of cell architecture (hypercontracture), sarinitial minutes of reperfusion, while cardiomyocytes re- 21 colemmal rupture and cell death [1] . Hypercontracture cover normal Ca homeostasis, contraction band necrosis causes an abrupt and extreme reduction of cell length and infarct size can be limited [6, 7] . However, complete contractile blockade requires regional, intracoronary administration of the blocker, and BDM, the only effective blocker of actin-myosin cycling so far available, has many and possesses a pharmacokinetic profile more favorable toxic effects.
than ANP, with a longer plasma half life [18, 19] , and it has We have previously shown that cGMP is reduced in been safely administered to patients [20] . myocardial cells after prolonged ischemia [8] , and that stimulation of cGMP synthesis at the time of re-energization has an inhibitory contractile effect in reperfused 2. Methods myocardium, being able to prevent re-energization induced hypercontracture in isolated cardiomyocytes [9] , isolated Animals were handled in accordance with the Guide for hearts [8] , and in situ hearts [10] . Cyclic GMP can be the Care and Use of Laboratory Animals published by the synthesized by either soluble or membrane-bound guanylyl US National Institutes of Health (NIH Publication No. cyclase (sGC and mGC, respectively) [11] . sGC activity 85-23, revised 1996) , and all experimental procedures can be stimulated by increasing NO availability either were approved by the Research Commission of the Hospidirectly, by NO donors, or indirectly, by increasing the tal General Vall d'Hebron. availability of L-arginine, the substrate for NO synthesis. The effect of administration of NO donors during reperfu-2.1. Studies in the isolated rat heart sion is controversial, probably due to potential harmful free radical effects of NO [12, 13] , interaction with the Hearts from male Sprague-Dawley rats, weighing 300-anion superoxide [14, 15] , and difficult control of the actual 350 g, were perfused with a modified Krebs-Henseleit amounts of NO released. L-Arginine supplementation has bicarbonate buffer (KHB) at 378C using a Langendorff been shown to protect against reperfusion-induced hyapparatus, at a constant pressure of 60 mmHg and LV percontracture by a cGMP dependent mechanism, and has pressure was monitored through the use of a water-filled consistently been found effective in limiting infarct size in latex balloon as previously described [8] . LV developed the in situ heart [10], but has to be administered before pressure was calculated as the difference between peak ischemia [16] .
systolic and end-diastolic values. A total of four sets of In the isolated, crystalloid-perfused rat heart submitted experiments were performed. In the first set of experiments to transient zero flow ischemia, stimulation of mGC with (n520), hearts were subjected to 40 min of ischemia and urodilatin, an ANP related peptide, at the time of reperfureperfused for 60 min, and were allocated to receive during sion induces a rapid increase in cGMP in reperfused the first 15 min of reperfusion urodilatin at the conmyocardium, and limits hypercontracture and cell death centration of 0 (control group), 0.01, 0.05 and 1 mmol / l. [8] . However, it is not known whether this approach is This series was used to assess the effect of different feasible during coronary reperfusion in vivo. To investiurodilatin concentrations on functional recovery. This gate this, the doses required to induce a sufficiently rapid effect cannot be assessed in the series submitted to 60 min and intense increase in cGMP concentration in reperfused of ischemia (see below) since after this duration, there is myocardium have to be determined. Administration of the virtually no recovery. In the second set of experiments largest tolerated doses may not be an adequate approach, (n516), the hearts were allocated to the same groups of since it has been suggested that a too intense stimulation of treatment but reperfusion was reduced to 10 min, and cGMP synthesis could be detrimental to reperfused myocardial cyclic GMP content was determined by 3 myocardium, and may result in enhanced apoptotic cell radioimmunoassay using acetylated [ H]cGMP, as prevideath [17] .
ously described [21] . In the third set of experiments (n5 The purpose of this study was to determine whether, and 22), ischemia was extended to 60 min, and lactate dehyat what doses, intravenous administration of urodilatin at drogenase (LDH) activity was spectrophotometrically meathe time of coronary reperfusion can protect myocardium sured in the coronary effluent as previously described [16] . against cell death. The relation between cGMP concenThe 60-min series was necessary to assess the reduction of tration in reperfused myocardium and the extent of LDH and necrosis by urodilatin, that were minimal in the myocardial cell death was investigated in isolated rat 40-min series. Finally, another group of rat hearts was hearts receiving different urodilatin concentrations at the submitted to 60 min of ischemia followed by 30 min of onset of reperfusion. The doses of intravenous urodilatin reperfusion, and were allocated (n54) to receive either necessary to obtain the targeted increase in cGMP in placebo or urodilatin 0.05 mM plus the ANP receptor reperfused myocardium were investigated in a series of antagonist isatin [22] during the first 15 min of reperfupigs submitted to transient coronary occlusion, and the sion. effect of two selected doses on infarct size was investigated in a larger series of experiments in this model.
Transient coronary occlusion in the in situ pig
Finally, an additional series of experiments in the isolated heart rat heart was used to confirm that the beneficial effect of urodilatin was mediated by stimulation of ANP receptors.
A total of 22 Large White pigs (34.761 kg) were Urodilatin is normally present in urine but not in blood, premedicated with 10 mg / kg azaperone i.m., anesthetized with thiopental 30 mg / kg i.v., intubated and mechanically [95-101] of urodilatin [20] . Plasma cGMP concentration ventilated with room air. Thiopental was used to maintain was measured by radioimmunoassay using acetylated 3 deep anesthesia. A midline sternotomy was performed and [ H]cGMP as previously described [21] . the left anterior descending coronary artery (LAD) was dissected free at its midpoint. Two pairs of ultrasonic 2.2.3. Myocardial cGMP content crystals inserted into the inner third of the left ventricular In order to measure myocardial cGMP concentration, wall were used to monitor myocardial segment length in frozen myocardial fragments were obtained from reperthe LAD and circumflex territory [6] . End-diastolic fused and control myocardium, pulverized under liquid (EDSL) and end-systolic segment length (ESSL) were nitrogen, and homogenized using cold trichloroacetic acid defined as the distance between crystals at end-diastole and at 7.5% (w / v). Cyclic GMP concentration was measured in end-systole, respectively. Systolic shortening was calcuthe homogenates as previously described [8] . lated as the difference between EDSL and ESSL divided by EDSL and expressed as %. A pressure transducer 2.2.4. Area at risk and infarct size catheter (Mikro-tip, Millar Instruments, TX, USA) was After 2 h of reperfusion the LAD was re-occluded and 5 advanced into the left ventricle, and a transit time flow ml of 10% fluorescein was injected into the left atrium. probe (T-106, Transonic Systems, NY, USA) was placed
The heart was excised, cooled at 48C, and cut into 5-7-mm around the LAD to monitor coronary blood flow. A slices perpendicular to its long axis. After being weighed thermometer placed in the esophagus was used to monitor in a precision balance (Precisa 180 A, Zurich, Switzerland) temperature.
the slices were illuminated from the basal side with ultraviolet light to outline the area at risk, and digital 2.2.1. Protocol images were obtained (Olympus Digital Camera C-1400L, Instrumentation was followed by a 30-min waiting time Olympus Optical, Tokyo, Japan). The slices were then after which the LAD was occluded during 47 min followed incubated at 378C for 10 min in 1% triphenyltetrazolium by reperfusion. The experiments were divided in two chloride (TTC) buffered at pH 7.4 and imaged again under series. In a first series of experiments ten animals were white light with a reference scale. The area at risk and the used to measure the effect of urodilatin on myocardial area of necrosis were measured in the digitized images cGMP content in reperfused and control myocardium.
using commercially available software (MicroImage, These animals were allocated to receive the placebo Olympus Optical, Hamburg, Germany). The masses of solution, urodilatin at a dose of 10 ng / kg per min or myocardium at risk and of the necrotic myocardium were urodilatin at a dose of 50 ng / kg per min during 10 min, calculated from these measurements and from the weight starting 5 min before coronary reperfusion. The apical of the slices as previously described [6] . portions of the ventricles (including the area at risk) were sectioned at 5 min of reperfusion with a dermatome blade 2.3. Statistical analysis and rapidly immersed in liquid nitrogen. The whole procedure lasted less than 5 s. In the second series of Investigators blind to treatment allocation performed all experiments, 22 animals had reperfusion time prolonged measurements. Statistical analysis was performed using for 2 h, and the effect on infarct size of two doses of commercially available software (SPSS for Windows 8.0). urodilatin was analyzed. A total of ten animals were
The homogeneity between groups was tested by ANOVA randomly allocated to receive urodilatin at a dose of 10 test for independent samples. Changes in segment length ng / kg per min or placebo during 30 min, starting 5 min and physiologic parameters were studied by means of the before reperfusion, and 12 animals were allocated at MANOVA test. Post-hoc analysis was performed by means random to receive either urodilatin at dose of 50 ng / kg per of the Scheffe test. A critical P-value of 0.05 was used for min or placebo. The drug was infused into a femoral vein all tests. All values are expressed as mean6S.E.M. (Harvard Syringe Infusion Pump 22, Harvard Apparatus, South Nathick, MA, USA).
Results

Plasma urodilatin and cGMP concentrations
Venous blood samples (5 ml) for urodilatin and cGMP 3.1. Studies in the isolated rat heart determination were withdrawn at 15 min before occlusion; at 10, 20, 30, 42, 44 and 47 min of coronary occlusion; and 3.1.1. Effects of urodilatin on myocardial function at 5, 15, 25, 27, 30, 35, 45, 60, 90 and 120 min of After 40 min of ischemia, LV end-diastolic pressure and reperfusion. The samples were placed in an ice-filled tray heart rate were identical in all groups of treatment, but LV and plasma was obtained in the following 30 min. Plasma developed pressure during reperfusion was significantly samples were stored at 2208C until processed. Plasma higher in hearts receiving 0.05 mM urodilatin during the urodilatin levels were measured by radioimmunoassay first 15 min of reperfusion (P50.01, Fig. 1 ). In hearts using a specific antibody against the NH terminal part submitted to 60 min of ischemia, there was virtually no sion, whereas cGMP content was well above control 
Studies in the in situ pig heart
during which the treatment solution was added to the reperfusion buffer. *P,0.05 compared to control.
Myocardial cGMP content
In animals allocated to 5 min of reperfusion and not recovery of contractile function after ischemia in any of receiving urodilatin, myocardial cGMP content was sigthe groups.
nificantly reduced in reperfused as compared to control myocardium (Fig. 4) . In animals receiving urodilatin at 10 3.1.2. LDH release ng / kg per min, myocardial levels of cGMP in the risk area In hearts subjected to 60 min of ischemia, reperfusion were nearly identical to those found in control myocardium was followed by a marked LDH release with a peak at 3 (Fig. 4) . In the urodilatin 50-ng / kg per min group, min of reperfusion. The addition of 0.05 mM urodilatin myocardial cGMP content in the risk area was much during the first 15 min of reperfusion significantly reduced LDH release (47.464.7 U / gdw per 30 min, vs. 69.664.5 U / gdw per 30 min in placebo group, P,0.01) (Fig. 2) , whereas no protective effect was observed with 0.01 and 1 mM urodilatin. No LDH release was found in the hearts submitted to 40 min of ischemia. The beneficial effects of 0.05 mM urodilatin on LDH release were abolished by the simultaneous administration of the ANP receptor inhibitor isatin (56.561.1 U / gdw per 30 min in hearts receiving urodilatin1isatin vs. 64.165.9 U / gdw per 30 min in the corresponding placebo group, P5NS).
Myocardial cyclic GMP content
Myocardial cyclic GMP content in hearts perfused under normoxic conditions for 50 min was 36.364.7 fmol / mg of protein. In hearts subjected to 40 min of ischemia and 10 min of reperfusion, and receiving 0 (placebo) or 0.01 mM of urodilatin, myocardial cGMP content was significantly reduced in reperfused myocardium, as compared to normoxic control myocardium (Fig. 3) . Cyclic GMP content normal values (17.262 mmHg at the end of the experiment). There were no differences between groups in coronary blood flow during reperfusion (Table 1) . higher than in control myocardium of the placebo group (3726100 vs. 111634 fmol / mg of protein, P50.06).
3.2.6. Regional wall function Changes in EDSL and systolic shortening during is-3.2.2. Infarct size studies chemia and reperfusion were similar in the three groups of As there were no differences in any of the investigated treatment (Table 1) . Coronary occlusion induced a rapid variables between placebo groups of the two doses of and marked increase in EDSL and abolition of systolic urodilatin investigated, control animals were grouped into shortening identical in all groups of treatment. Reperfusion one single placebo group. Results are thus referred to three induced an immediate reduction of EDSL at 5 min groups: placebo, urodilatin 10 ng / kg per min and (9163% of basal value) that was followed by a trend urodilatin 50 ng / kg. towards normalization during the rest of reperfusion, without differences between groups. There was no signifi-3.2.3. Blood chemistry and hematological determinations cant recovery of contractile function during reperfusion in There were no significant changes in hematocrit, platelet any of the groups. count, glucose, potassium, sodium or urea plasma conChanges in the amplitude of segment length change centrations throughout the experiment in any of the groups observed during coronary occlusion were similar in all of treatment.
groups. In all animals, the amplitude of segment length change remained stable during the first minutes of is-3.2.4. Plasma levels of urodilatin chemia and then showed a progressive reduction reflecting Intravenous urodilatin infusion was followed by a dosethe development of rigor contracture [23] . This reduction dependent increase in plasma urodilatin concentration in started 18.861.2 min after coronary occlusion, without both treatment groups (Fig. 5) .
differences between groups (P50.941). At 40 min of coronary occlusion, the amplitude of segment length was 3.2.5. Hemodynamics and coronary blood flow 50.167.4% of that measured after 5 min of ischemia, Heart rate and mean aortic pressure were similar in all without differences between groups. groups throughout the experiment, with a progressive Segment length measurements in the circumflex territory increase with respect to basal values during the occlusion were nearly identical in all groups. End-diastolic length period and the first 15 min of reperfusion. After that, heart was 101.660.8% of initial length after 5 min of coronary rate and mean artery pressure remained stable (Table 1) . occlusion, 101.560.7% after 48 min, and 99.660.9 after 2 Changes in LV pressure during ischemia-reperfusion were h of reperfusion. Systolic shortening was also similar in the different groups of treatment: 102.966.2% of initial the ventricles (weight 14.260.9 g) without differences value after 5 min of coronary occlusion, 99.564.7% after between groups (P50.25). Infarct size, defined as a 48 min, and 8768.0% at the end of the experiment percent of myocardium at risk developing necrosis, was (P5NS).
significantly smaller in animals receiving urodilatin at 10 ng / kg per min during the first 25 min of reperfusion than 3.2.7. Arrhythmias in those receiving placebo. In the group receiving 50 All animals presented ventricular ectopic beats during ng / kg per min of urodilatin there was a non-significant the coronary occlusion period and runs of idioventricular trend towards a reduced infarct size (Fig. 7) . accelerated rhythm during early reperfusion. A total of four animals (one in the placebo group, one receiving urodilatin 10 ng / kg per min and two receiving urodilatin 50 ng / kg 4. Discussion per min) presented ventricular fibrillation during the occlusion period at a mean time of 2765 min. In the first minute
In previous studies it has been shown that stimulation of of reperfusion four animals developed ventricular fibrillacGMP synthesis by enhancing NO availability or by tion (two in the placebo, one in the urodilatin 10 ng / kg per min and one in the urodilatin 50-ng / kg per min groups, respectively).
cGMP concentration
Plasma cGMP concentration showed a rapid increase after the onset of the urodilatin infusion and reached its maximal value at 30 min of reperfusion (Fig. 6) . In the urodilatin 10-ng / kg per min group, plasma levels rose from 37.4611 to 76.3611 pmol / ml (P50.01), whereas in the urodilatin 50-ng / kg per min group, plasma levels rose from 54.0614.8 to 123.8613.7 pmol / ml (P50.008). Plasma levels of cGMP showed no significant increase after the placebo infusion (from 41.2610 to 35.165.3, P50.594). administered at the time of reperfusion. Second, studies on the effect of inhibitors of NO synthesis on myocardial injury secondary to transient ischemia have yielded controversial results [14, 26, 29] , and in several instances have observed a clear protective effect of these drugs [25, 29] . NO can protect cells from superoxide free radical toxicity [14] , but can also behave itself like a toxic radical [30] either directly, or through generation (by reacting with superoxide anion) of peroxynitrite [31] . These effects could outbalance other cGMP-mediated beneficial effects. Finally, although NO donors have been administered to patients with acute myocardial infarction receiving reperfusion therapy in two large clinical trials (ISIS-4 and GISSI-3), it is not possible to draw conclusions from these studies regarding the potential role of NO donors in the prevention of reperfusion injury [32, 33] . This is mainly due to the late Error bars indicate S.E.M. administration of the donors (up to 24 h after reperfusion therapy) in these trials, the high rate of cross-over between stimulation of membrane guanylate cyclase (mGC) with treatment groups, the large number of patients receiving urodilatin limited hypercontracture and cell death during NO donors in the control group, and the concomitant use reoxygenation or reperfusion in the isolated rat heart of ACE inhibitors. limitation of neutrophil-mediated injury [12, 24] . However, Higher doses of urodilatin resulting in elevation of cGMP this mechanism cannot explain the beneficial effect of in reperfused myocardium well above normal values these interventions in in vitro systems or in crystaloid attenuate or abolish this beneficial effect.
perfused preparations [14, 16, 26] . We have proposed that the protective effect of these interventions would be 4.1. Stimulation of cGMP during myocardial ischemiamediated, at least in part, by a direct effect of cGMP on reperfusion: previous studies cardiomyocytes [16] . In the present study, the cause / effect relationship beThere is ample and basically coherent information tween cGMP increase and the beneficial effects of regarding the effect of maneuvers increasing cGMP conurodilatin was supported by the lack of effects of too low centration on myocardial cell death secondary to ischemiadoses that failed to normalize myocardial cGMP in perreperfusion [12, [24] [25] [26] [27] [28] . In most studies, L-arginine supplefused myocardium, and by the fact that the beneficial effect mentation has been found to exert a protective effect of urodilatin was abolished by ANP receptor blockade. against cell death secondary to transient anoxia or ischemia Stimulating cGMP synthesis has been found to protect in different animal species [10, 16, 24, 25] . However, most against reoxygenation induced hypercontracture in isolated studies indicate that L-arginine has to be administered cardiomyocytes and in isolated perfused rat hearts [8,9]. before energy deprivation in order to be effective, which This effect can be mimicked by administration of the limits its potential therapeutic value in the treatment of soluble cGMP analog 8-Br-cGMP [8] , and can be patients with acute myocardial infarction.
abolished by inhibitors of cGMP synthesis [16] . Cyclic The effect of direct stimulation of sGC with NO donors GMP has been described to have a negative inotropic on ischemia-reperfusion injury has been investigated in in effect [34] . Although this effect is small in normal vitro models [1, 12, 14, 26] and in different animal species myocardium under normoxic conditions, it could be larger [27, 28] , and a large majority of these studies have demonin reperfused myocardium, in which myofilament sensitivi-21 strated a protective effect. However, some points regarding ty to Ca is already depressed (stunning). A significant the beneficial effect of NO donors remain obscure. First, negative inotropic effect of urodilatin in reperfused, but few studies have analyzed the effect of NO donors not in control myocardium, has been previously shown in the isolated rat heart [8]. This negative inotropic effect patients with acute myocardial infarction is not warranted seems to be due to a desensitizing effect of cGMP on due to potential interspecies differences, and to particular myofilaments [34] . This desensitization effect could be features of acute coronary thrombosis in the context of mediated by cytosolic acidification, since cGMP dependent human coronary heart disease not adequately reproduced in [38] . (CICYT). Previous studies on the effects of ischemia and reperfusion on myocardial cGMP content are scant and contradictory [39, 40] . This and previous studies from our group References demonstrate that ischemia induces a severe reduction in myocardial cGMP concentration [8, 10] , and that altered´´ accounting for less than 5% of cells in myocardial tissue The present study demonstrates that the intravenous 
